MSD Has Appealed The Denial Of Injunction Against Glenmark, In India

Merck’s Indian subsidiary (MSD India) yesterday appealed the denial of the temporary relief against Glenmark — related to Glenmark’s “at risk” launch of sitagliptin tablets. As that appeal wends its way through the Indian appellate courts, the underlying patent suit will continue to work its way toward a trial date. All the while, Glenmark will keep track of its sitaglipin sales in India, in the event that it is ultimately ordered to pay a royalty of some kind, to MSD, in the end.

Here is that MSM report. Not much additional news, there. So here’s another one. I think this storyline will likely run silent for a bit.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s